Provided by Tiger Trade Technology Pte. Ltd.

Immunovant, Inc.

33.78
+0.32000.96%
Post-market: 33.780.00000.00%16:33 EDT
Volume:1.43M
Turnover:48.41M
Market Cap:6.97B
PE:-11.99
High:34.20
Open:33.62
Low:33.12
Close:33.46
52wk High:45.42
52wk Low:15.95
Shares:206.40M
Float Shares:89.57M
Volume Ratio:0.72
T/O Rate:1.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8178
EPS(LYR):-2.7716
ROE:-80.10%
ROA:-46.73%
PB:9.48
PE(LYR):-12.19

Loading ...

Immunovant (IMVT) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Sep 26

Bernstein Reaffirms Their Hold Rating on Immunovant (IMVT)

TIPRANKS
·
Sep 26

Immunovant Down over 7%, on Pace for Largest Percent Decrease Since July 2025

Dow Jones
·
Sep 24

Immunovant Stock Slides After Biotech Scraps Autoimmune Drug Program

Dow Jones
·
Sep 24

Analysts Are Bullish on These Healthcare Stocks: Immunovant (IMVT), Oruka Therapeutics (ORKA)

TIPRANKS
·
Sep 24

Immunovant Proof-of-Trial for IMCT-1402 Misses Primary Endpoint

Dow Jones
·
Sep 23

Sector Update: Healthcare

MT Newswires Live
·
Sep 23

Update: US Equity Futures Slightly Lower Pre-Bell as Traders Await Developments in US-Iran Talks

MT Newswires Live
·
Sep 23

Immunovant Falls After Lupus Drug Setback

Reuters
·
Sep 23

Roivant announces trial of IMVT-1402 did not reach statistical significance

TIPRANKS
·
Sep 23

Immunovant Announces Topline Results from Proof-of-Concept Study of Imvt-1402 in Cutaneous Lupus Erythematosus

THOMSON REUTERS
·
Sep 23

Immunovant, - Imvt-1402 Study in Cle Did not Achieve Statistical Significance on Primary Endpoint

THOMSON REUTERS
·
Sep 23

Immunovant, - to Stop Development of Imvt-1402 in Cle

THOMSON REUTERS
·
Sep 23

Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

GlobeNewswire
·
Sep 23

Analysts’ Top Healthcare Picks: LeonaBio (LONA), Immunovant (IMVT)

TIPRANKS
·
Sep 21

Immunovant Holds Annual Stockholder Meeting with 96% Shares Represented

Reuters
·
Sep 04

Roivant Sciences President, Immunovant CEO Eric Venker Disposes of Common Shares Worth $7.15 Million

Reuters
·
Sep 02

Immunovant Director Atul Pande Disposes of 1,500 Common Shares Worth $64,905

Reuters
·
Aug 29

Immunovant's Risk/Reward Profile Balanced After Recent Rally, UBS Says

MT Newswires Live
·
Aug 25

UBS Adjusts Immunovant Price Target to $40 From $24, Maintains Neutral Rating

MT Newswires Live
·
Aug 24